DRREDDY : CLARIFIES NEWS ON $40 HIV PREVENTION SHOT US FDA NOD

• Company confirms First Post headline on US nod for $40 generic HIV prevention shot for 120 poorer countries is correct • News pertains to Nov 2, 2026 press release on US FDA tentative approval for twice-yearly injectable lenacapavir • Approval advances access to HIV prevention across 120 countries outside the US • Company says matter does not constitute a material event or information under SEBI Reg 30 • Company sees no material impact of the news article on the company Impact: Neutral (Clarification confirms FDA tentative approval but company says no material impact)

Dr. Reddy's Laboratories Limited

Open attachment

← Back to feed